Crown Therapeutics, a division of Crown Laboratories, is proud to announce that PanOxyl® is expanding its award-winning portfolio with its new PM Balancing Repair Moisturizer and reformulating the existing AM Oil Control Moisturizer.
CG Oncology, Inc. announced updated data from the CORE-001 study, an ongoing Phase 2 clinical trial of cretostimogene grenadenorepvec (CG0070) in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab), for the treatment of patients with non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG).
Kiromic BioPharma, Inc. today announces that the U.S. Food and Drug Administration (FDA) has authorized the Company’s Investigational New Drug (IND) application to initiate a Phase 1 clinical trial to evaluate Deltacel (KB-GDT-01) for patients with non-small cell lung cancer (NSCLC).
Pulse Biosciences, Inc. today announced that it has entered into a stock purchase agreement with Robert W. Duggan, an experienced life sciences executive and the Company’s Executive Chairman, for the purchase of 10,022,937 shares of the Company’s common stock.
Pulse Biosciences Announces $65 Million Private Placement Read More »
Tempus today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s first Premarket Approval (PMA) application for its companion diagnostic test, xT CDx . xT CDx is a 648-gene next-generation sequencing test for solid tumor profiling, which includes microsatellite instability status and companion diagnostic claims for colorectal cancer patients.
Tempus Receives U.S. FDA Approval for xT CDx, a NGS-Based In Vitro Diagnostic Device Read More »
Horizon Therapeutics plc Announces Initiation of Phase 3 Clinical Trial in Japan Evaluating TEPEZZA ® (teprotumumab-trbw) in Adults with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED).
Inspirna, Inc. announced today the appointment of Dr. Usman “Oz” Azam, M.D., as its new Chief Executive Officer.
Inspirna Appoints Dr. Usman “Oz” Azam, M.D., as New Chief Executive Officer Read More »
bioAffinity Technologies, Inc. today announced that Michael Dougherty has joined the company as Chief Financial Officer, effective today.
bioAffinity Technologies Names Michael Dougherty as Chief Financial Officer Read More »
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of Accugenix® Next Generation Sequencing for Bacterial Identification and Fungal Identification (Accugenix® NGS).
Otsuka and Lundbeck won approval Friday for Abilify Asimtufii, a long-acting injectable that provides two months of symptom relief in patients with schizophrenia or bipolar I disorder.
FDA Greenlights First Bi-Monthly Injectable for Schizophrenia, Bipolar 1 Disorder Read More »
